Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


22.05.2017

1 BJU Int
1 Cancer Res
1 Eur Radiol
7 Eur Urol
1 Hum Pathol
1 Int J Cancer
4 J Nucl Med
7 J Urol
2 Nat Rev Urol
1 Oncology (Williston Park)
1 Prostate
1 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. HEDDEN L, Wassersug R, Mahovlich S, Pollock P, et al
    Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners.
    BJU Int. 2017 May 17. doi: 10.1111/bju.13885.
    PubMed     Text format     Abstract available


    Cancer Res


  2. Correction: Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells.
    Cancer Res. 2017;77:2772.
    PubMed     Text format    


    Eur Radiol

  3. GIGANTI F, Moore CM, Robertson NL, McCartan N, et al
    MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial.
    Eur Radiol. 2017 May 18. doi: 10.1007/s00330-017-4858.
    PubMed     Text format     Abstract available


    Eur Urol

  4. SEYEDNASROLLAH F, Mahmoudian M, Rautakorpi L, Hirvonen O, et al
    Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prost
    Eur Urol. 2017 May 9. pii: S0302-2838(17)30341.
    PubMed     Text format    

  5. MIRTTI T, Aittokallio T
    Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40.
    Eur Urol. 2017 May 9. pii: S0302-2838(17)30340.
    PubMed     Text format    

  6. MITRAKAS L
    Re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol 2017;71:267-73.
    Eur Urol. 2017 May 10. pii: S0302-2838(17)30345.
    PubMed     Text format    

  7. CHUA MLK, Lo W, Pintilie M, Murgic J, et al
    A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
    Eur Urol. 2017 May 13. pii: S0302-2838(17)30344.
    PubMed     Text format     Abstract available

  8. HADASCHIK B, Herrmann K
    Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30388.
    PubMed     Text format    

  9. BECK M, Hayoz S, Ghadjar P
    Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30385.
    PubMed     Text format    

  10. HERMANNS T, Poyet C
    The Next Generation of Prostate Cancer Risk Calculators.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30387.
    PubMed     Text format    


    Hum Pathol

  11. RONEN S, Abbott DW, Kravtsov O, Abdelkader A, et al
    PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform.
    Hum Pathol. 2017 May 10. pii: S0046-8177(17)30154.
    PubMed     Text format     Abstract available


    Int J Cancer

  12. WANG Y, Freedman JA, Liu H, Moorman PG, et al
    Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30787.
    PubMed     Text format     Abstract available


    J Nucl Med

  13. LIN C, Bradshaw TJ, Perk TG, Harmon S, et al
    Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
    J Nucl Med. 2016 Jul 21. pii: jnumed.116.177295.
    PubMed     Text format     Abstract available

  14. HADASCHIK B, Boegemann M
    Why Targeting PSMA is a valuable addition in the management of castration-resistant prostate cancer: The Urologists' point of view.
    J Nucl Med. 2017 May 18. pii: jnumed.117.194753. doi: 10.2967/jnumed.117.194753.
    PubMed     Text format    

  15. SCHMUCK S, von Klot CA, Henkenberens C, Sohns JM, et al
    Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.
    J Nucl Med. 2017 May 18. pii: jnumed.117.193581. doi: 10.2967/jnumed.117.193581.
    PubMed     Text format     Abstract available

  16. HOPE TA, Aggarwal R, Chee B, Tao D, et al
    Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2017 May 18. pii: jnumed.117.192476. doi: 10.2967/jnumed.117.192476.
    PubMed     Text format     Abstract available


    J Urol

  17. TANEJA SS
    Re: Mortality among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    J Urol. 2017;197:1456-1457.
    PubMed     Text format    

  18. TANEJA SS
    Re: Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
    J Urol. 2017;197:1456.
    PubMed     Text format    

  19. CADEDDU JA
    Re: Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    J Urol. 2017;197:1457-1458.
    PubMed     Text format    

  20. ATALA A
    Re: Activation of Notch1 Synergizes with Multiple Pathways in Promoting Castration-Resistant Prostate Cancer.
    J Urol. 2017;197:1458-1459.
    PubMed     Text format    

  21. ATALA A
    Re: Androgen Receptor Antagonists Compromise T Cell Response against Prostate Cancer Leading to Early Tumor Relapse.
    J Urol. 2017;197:1459.
    PubMed     Text format    

  22. KAPLAN SA
    Re: Interactions between Benign Prostatic Hyperplasia (BPH) and Prostate Cancer in Large Prostates: A Retrospective Data Review.
    J Urol. 2017;197:1531-1532.
    PubMed     Text format    

  23. SEFTEL AD
    Re: Rasch Analysis of the Premature Ejaculation Diagnostic Tool (PEDT) and the International Index of Erectile Function (IIEF) in an Iranian Sample of Prostate Cancer Patients.
    J Urol. 2017;197:1534-1535.
    PubMed     Text format    


    Nat Rev Urol

  24. SAAD F
    Prostate cancer: 'The prostate' in patients with metastatic prostate cancer: to treat or not to treat?
    Nat Rev Urol. 2017 May 16. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  25. THOMA C
    Prostate cancer: Circulating free DNA as biomarker.
    Nat Rev Urol. 2017 May 16. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    Oncology (Williston Park)

  26. GARISTO JD, Klotz L
    Active Surveillance for Prostate Cancer: How to Do It Right.
    Oncology (Williston Park). 2017;31.
    PubMed     Text format     Abstract available


    Prostate

  27. MIYAHIRA AK, Soule HR
    The 23rd Annual Prostate Cancer Foundation Scientific Retreat report.
    Prostate. 2017 May 14. doi: 10.1002/pros.23366.
    PubMed     Text format     Abstract available


    Radiology

  28. PAHWA S, Schiltz NK, Ponsky LE, Lu Z, et al
    Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men.
    Radiology. 2017 May 17:162181. doi: 10.1148/radiol.2017162181.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: